<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="136530">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01323959</url>
  </required_header>
  <id_info>
    <org_study_id>113060</org_study_id>
    <nct_id>NCT01323959</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults</brief_title>
  <official_title>Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will evaluate the persistence of immune response against diphtheria, tetanus,
      pertussis and poliomyelitis in healthy adults, 10 years after a booster dose, and also
      assess the immunogenicity and safety of another booster dose of BoostrixTM Polio.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol posting has been updated following protocol amendment 1, dated 03 June 2011.
      The impacted section is: Eligibility Criteria (Exclusion criteria).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity with respect to booster vaccination.</measure>
    <time_frame>One month (Month 1) after a booster dose of BoostrixTM Polio vaccine</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune persistence after the booster dose given in the study NCT01277705</measure>
    <time_frame>Before (Day 0) a booster dose of BoostrixTM Polio vaccine</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to booster vaccination.</measure>
    <time_frame>One month (Month 1) after the booster dose of BoostrixTM Polio vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited local and general symptoms.</measure>
    <time_frame>During the 4-day (Day 0-3) follow-up period after booster vaccination.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited adverse events.</measure>
    <time_frame>During the 31-day (Day 0-30) follow-up period after booster vaccination.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>From the booster dose (Day 0) up to study end (Month 1)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Acellular Pertussis</condition>
  <condition>Poliomyelitis</condition>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BoostrixTM Polio</intervention_name>
    <description>Single dose, intramuscular administration.</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes can and will comply with the requirements of
             the protocol.

          -  Male or female subjects who have received vaccine in study NCT01277705.

          -  Written informed consent obtained from the subject.

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study.

          -  Female subjects of non-childbearing potential may be enrolled in the study.

          -  Female subjects of childbearing potential may be enrolled in the study and receive
             the booster vaccine, if the subject:

               -  practices/has practiced adequate contraception for 30 days prior to vaccination,
                  and

               -  has a negative pregnancy test on the day of vaccination, and

               -  agrees to continue adequate contraception during the entire booster epoch.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine
             within 30 days preceding the booster dose of the study vaccine, or planned use during
             the study period.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the booster dose.

          -  Administration of a vaccine not foreseen by the study protocol within 30 days prior
             to booster vaccination, or planned administration during the active study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product.

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccine.

          -  Previous booster vaccination against diphtheria, tetanus, pertussis or poliovirus
             since the dose received in study NCT01277705. In Germany, previous dose of a
             monovalent vaccine against pertussis is allowed for subjects in the Group C.

          -  History of diphtheria, tetanus, pertussis or poliomyelitis diseases following the
             receipt of booster dose in study NCT01277705.

          -  Any confirmed or suspected immunosuppressive or immunodeficiency condition based on
             medical history and physical examination.

          -  Occurrence of transient thrombocytopenia or neurological complications following an
             earlier immunisation against diphtheria and/or tetanus.

          -  Occurrence of any of the following adverse event after a previous administration of a
             DTP vaccine:

               -  Hypersensitivity reaction to any component of the vaccine,

               -  encephalopathy of unknown aetiology occurring within seven days following
                  previous vaccination with pertussis-containing vaccine,

               -  fever ≥ 40°C within 48 hours of vaccination not due to another identifiable
                  cause,

               -  collapse or shock-like state within 48 hours of vaccination,

               -  convulsions with or without fever, occurring within 3 days of vaccination.

          -  Administration of immunoglobulins and/or any blood products within the three months
             preceding the booster dose or planned administration during the study period.

          -  Acute disease and/or fever at the time of enrolment.

          -  Pregnant or lactating female.

          -  Female planning to become pregnant or planning to discontinue contraceptive
             precautions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Derval</city>
        <zip>44590</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Chapelle Basse Mer</city>
        <zip>44450</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Riche</city>
        <zip>37250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes cedex 2</city>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tours</city>
        <zip>37200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deggendorf</city>
        <state>Bayern</state>
        <zip>94469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoehenkirchen-Siegertsbrunn</city>
        <state>Bayern</state>
        <zip>85635</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Selbitz</city>
        <state>Bayern</state>
        <zip>95152</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilshofen</city>
        <state>Bayern</state>
        <zip>94474</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weilheim</city>
        <state>Bayern</state>
        <zip>82362</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 29, 2016</lastchanged_date>
  <firstreceived_date>March 24, 2011</firstreceived_date>
  <firstreceived_results_disposition_date>July 26, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BoostrixTM Polio</keyword>
  <keyword>dTpa-IPV</keyword>
  <keyword>booster</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>113060</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113060</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113060</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113060</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113060</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>113060</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
